drugset / Trial / NCT05969184
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
NaSingle-groupOpen-labelTreatment
Summary
This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
Timeline
- Start
- 2021-12-12
- Primary completion
- 2026-04-25
- Completion
- 2026-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |